<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene T95I;Y144delinsTSN;R346K;E484K;N501Y;D614G;P681H;D950N literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.T95I;Y144delinsTSN;R346K;E484K;N501Y;D614G;P681H;D950N</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Mean 12.4x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset. [This is a greater reduction than Beta @ 8.2x] (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using live B.1.621 virus and a cytopathic effect-based assay, sera from 37 Pfizer/BioNTech BNT162b2 vaccinees collected 10-20 days post-booster showed significantly lower (95) but still "robust" neutralization than against ancestral B.1 virus (107).<br/> (<a href="https://doi.org/10.1002/jmv.27247" class="lit_link">Messali et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mean 7.6x reduction of NT50 value B.1.621 (Mu) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster. [This is a greater reduction than Beta @ 6.3x] (<a href="https://doi.org/10.1101/2021.09.06.459005" class="lit_link">Uriu et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
